Wedbush reissued their outperform rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a research ...
Servier will be responsible for development and global commercialisation of the therapy for several indications.
The city of Black Diamond has begun a fire protection and emergency services feasibility study in the midst of potentially ...
Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Black Diamond Therapeutics in a ...
A marketing expert reacts to an image of see-through Black Diamond American cheese, claiming it could be a result of ...
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...
Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.
This recall involves all BD Vision Harnesses. This lightweight harness is designed for technical alpine and ice climbs. All ...
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with ...
Black Diamond Equipment has announced a recall of all BD Vision Harnesses due to a potential fall hazard. This action is ...